drugset / Trial / NCT03756974
BX-1 in Spasticity Due to Multiple Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the efficacy and safety of orally administered BX-1 compared to placebo in patients with spasticity due to multiple sclerosis not sufficiently controlled by current anti-spasticity medication
Timeline
- Start
- 2019-02-18
- Primary completion
- 2021-03-30
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronabinol | Other / unclassified | — | Oral |
Indications
No indication recorded.